Case report
Case Report: Binding of a Clinically Relevant Human Leukocyte Antigen–DQα–Specific Antibody in a Kidney Graft Recipient is Inhibited by Donor-Type Human Leukocyte Antigen–DQβ Chain

https://doi.org/10.1016/j.transproceed.2012.10.006Get rights and content

Abstract

In this case report, we have found what may be an immunization with donor-specific human leukocyte antigen (HLA)-DQα in combination with recipient-specific HLA-DQβ. A renal allograft recipient who did not comply with immunosuppressive therapy during pregnancy had graft failure 23 months posttransplantation with biopsy-proven humoral and cellular rejection. Sera were tested in a Luminex-based single-antigen bead assay. We compared Luminex reactivity with the degree of eplet mismatching between the recipient's own HLA-DQ chains and the HLA-DQ chains bound to the Luminex beads. Eplet calculations were done with the HLAMatchmaker. HLA-DQ similarities were compared further by dissimilarity scoring in HistoCheck. We observed that Luminex beads with donor-type HLA-DQα and HLA-DQβ bound less antibody than beads with donor-type HLA-DQα combined with recipient HLA-DQβ. In HLAMatchmaker, we identified all eplet mismatches between donor and recipient HLA-DQ. Next, we counted how many of these eplets were represented on the various Luminex beads. We found that antibody binding to the bead increased with the number of such mismatches for HLA-DQα. Surprisingly, antibody binding decreased as the number of eplet mismatches for HLA-DQβ increased, from a mean fluorescence intensity (MFI) value of 18,800 for no mismatched eplets to approximately 10,000 for 12 mismatched eplets. These findings were confirmed by comparing antibody binding with the structural dissimilarity score between the recipient HLA-DQ type and the HLA-DQ bound to the Luminex beads. In this patient, clinically relevant antibodies bound strongly to donor-like HLA-DQα chains when combined with recipient-like HLA-DQβ. HLA-DQβ chains more similar to those of the donor reduced the binding of donor- specific HLA-DQα antibody.

Section snippets

Case Description

A 34-year-old woman received her first renal allograft from a blood type–identical deceased donor in 2010. The patient type was HLA-A2,30(19); B18,44(12); DRB1*03; DQB1*02 and the donor type was HLA- A3,32(19); B44(12),57(17); DR07, 12; DQB1*03:01,03:03.

In pretransplantation serum of the patient, no HLA class I or class II antibodies were detected using complement-dependent cytotoxic (CDC) technique. Pretransplantation CDC crossmatch was negative against both T cells and B cells.

During

Methods

HLA antibodies in posttransplantation serum of the patient were detected with the Luminex single-antigen bead assay LABScreen. HLA-coated beads enabled identification of Immunoglobulin G (IgG) alloantibody specificities against HLA-A,-B,-C,-DRB1,-DQA1,-DQB1 antigens. The threshold for a positive response was set at a mean fluorescence intensity (MFI) of 1000.

High-resolution DQA1/DQB1 typing was done with single specific primer-polymerase chain reaction technique. The patient type was HLA-

Results

The Luminex assay on the 23-month posttransplantation serum of the patient revealed anti-DQ2 autoreactive antibodies (MFI 12,000–18,000) when using beads with the serological equivalent of HLA-DQβ. Considering both DQβ and DQα chains, the strongly reactive anti-DQ2 antibodies bound only to beads with recipient-type DQβ chains in combination with nonself DQα chains. The patient had no anti-DQ2 antibodies against the beads with self-type DQα/DQβ.

Examining DQβ chains and their serological

Discussion

Herein, we have demonstrated a surprising binding of an anti-HLA DQ antibody dependent on similarity to donor DQα chain and to recipient DQβ chain.

The Luminex analysis revealed anti-DQ7 and anti-DQ9 reactivity examining only the DQβ chains and their serological equivalents. The patient had antibodies against all beads coated with donor-identical DQα chains, so examining the DQβ as well as the DQα chains, the patient had broadly reactive DSAs. This indicates that the serological nomenclature is

Acknowledgments

We thank the staff at the Tissue Typing Laboratory for their technical assistance.

References (12)

There are more references available in the full text version of this article.

Cited by (0)

View full text